AR104156A1 - Anticuerpos monoclonales anti-cd303 - Google Patents

Anticuerpos monoclonales anti-cd303

Info

Publication number
AR104156A1
AR104156A1 ARP160100871A ARP160100871A AR104156A1 AR 104156 A1 AR104156 A1 AR 104156A1 AR P160100871 A ARP160100871 A AR P160100871A AR P160100871 A ARP160100871 A AR P160100871A AR 104156 A1 AR104156 A1 AR 104156A1
Authority
AR
Argentina
Prior art keywords
variable region
chain variable
region comprises
sequence seq
heavy chain
Prior art date
Application number
ARP160100871A
Other languages
English (en)
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54937151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104156(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of AR104156A1 publication Critical patent/AR104156A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Anticuerpo monoclonal dirigido contra el ectodominio del antígeno CD303 humano (SEC ID nº 130), o un fragmento funcional o un derivado de éste, caracterizado por que: a) entra en competición para la unión al antígeno CD303 humano con por lo menos un anticuerpo seleccionado de entre: i) un anticuerpo cuya región variable de cadena pesada comprende la secuencia SEC ID nº 43 y la región variable de cadena ligera comprende la secuencia SEC ID nº 48; ii) un anticuerpo cuya región variable de cadena pesada comprende la secuencia SEC ID nº 44 y la región variable de cadena ligera comprende la secuencia SEC ID nº 49; iii) un anticuerpo cuya región variable de cadena pesada comprende la secuencia SEC ID nº 45 y la región variable de cadena ligera comprende la secuencia SEC ID nº 50; iv) un anticuerpo cuya región variable de cadena pesada comprende la secuencia SEC ID nº 46 y la región variable de cadena ligera comprende la secuencia SEC ID nº 51; v) un anticuerpo cuya región variable de cadena pesada comprende la secuencia SEC ID nº 47 y la región variable de cadena ligera comprende la secuencia SEC ID nº 52; y b) las regiones constantes de las cadenas ligeras y de las cadenas pesadas son unas regiones constantes que proceden de una especie no murina. Reivindicación 23: Ácido nucleico que codifica para la cadena pesada y/o la cadena ligera de un anticuerpo, fragmento funcional o derivado de éste según cualquiera de las reivindicaciones 1 a 22. Reivindicación 25: Vector que comprende un ácido nucleico según la reivindicación 23 o la reivindicación 24. Reivindicación 26: Célula hospedante, animal no-humano transgénico o planta transgénica que comprende por lo menos un ácido nucleico según la reivindicación 23 o la reivindicación 24 o un vector según la reivindicación 25.
ARP160100871A 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303 AR104156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552757A FR3034420A1 (fr) 2015-03-31 2015-03-31 Anticorps monoclonaux anti-cd303

Publications (1)

Publication Number Publication Date
AR104156A1 true AR104156A1 (es) 2017-06-28

Family

ID=54937151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100871A AR104156A1 (es) 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303

Country Status (13)

Country Link
US (3) US10239946B2 (es)
EP (2) EP3277723B1 (es)
JP (2) JP2018511328A (es)
KR (1) KR20170132819A (es)
CN (1) CN107660212A (es)
AR (1) AR104156A1 (es)
AU (1) AU2016239936A1 (es)
BR (1) BR112017020698A2 (es)
CA (1) CA2981093A1 (es)
ES (1) ES2819902T3 (es)
FR (2) FR3034420A1 (es)
MX (2) MX2017012399A (es)
WO (2) WO2016156450A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) † 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
FR3060395B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
EP3735425A1 (en) * 2018-01-04 2020-11-11 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for bdca2 antigen
CA3138501A1 (en) 2019-06-13 2020-12-17 Thomas Charles PERTEL Anti-talen antibodies and uses thereof
CN114516915B (zh) * 2020-11-19 2023-03-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体以及制备抗体的方法
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116693687B (zh) * 2023-08-03 2023-10-03 天津旷博同生生物技术有限公司 一种抗人cd25工程抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
JP4523165B2 (ja) 1998-11-02 2010-08-11 トラスティーズ オブ タフツ カレッジ トランスジェニックおよびクローン哺乳動物
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2382741A1 (en) 1999-10-14 2001-04-19 Genzyme Transgenics Corporation Methods of producing a target molecule in a transgenic animal and purification of the target molecule
EP1783141A1 (en) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP2354149B1 (en) 2000-12-12 2017-08-30 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
EP1565564A4 (en) 2002-11-27 2006-06-07 Gtc Biotherapeutics Inc STILK-STABILIZED ANTIBODIES PRODUCED IN MILK AND METHOD FOR THE MANUFACTURE THEREOF
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004278747B2 (en) 2003-09-30 2011-04-28 Sterrenbeld Biotechnologie North America, Inc. A process for producing exogenous protein in the milk of transgenic mammals and a process for purifying proteins therefrom
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
DK1945666T3 (da) 2005-10-21 2013-07-01 Genzyme Corp Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
KR20150126730A (ko) 2006-09-10 2015-11-12 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
PE20150682A1 (es) 2008-10-14 2015-05-20 Genentech Inc Variantes de inmunoglobulinas y sus usos
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2981946B1 (fr) 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
FR2986536A1 (fr) 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
US9175691B2 (en) * 2012-10-03 2015-11-03 Praxair Technology, Inc. Gas compressor control system preventing vibration damage
WO2014093396A1 (en) * 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303

Also Published As

Publication number Publication date
US10611843B2 (en) 2020-04-07
US10239946B2 (en) 2019-03-26
AU2016239936A1 (en) 2017-10-12
JP2018512144A (ja) 2018-05-17
US20180086834A1 (en) 2018-03-29
EP3277723B1 (fr) 2020-06-17
CA2981093A1 (fr) 2016-10-06
EP3277720A1 (fr) 2018-02-07
KR20170132819A (ko) 2017-12-04
EP3277723A1 (fr) 2018-02-07
ES2819902T3 (es) 2021-04-19
BR112017020698A2 (pt) 2018-06-26
CN107660212A (zh) 2018-02-02
US20180066060A1 (en) 2018-03-08
JP2018511328A (ja) 2018-04-26
MX2017012399A (es) 2018-01-26
WO2016156449A1 (fr) 2016-10-06
FR3034430A1 (fr) 2016-10-07
FR3034420A1 (fr) 2016-10-07
FR3034430B1 (fr) 2024-03-29
US20200277385A1 (en) 2020-09-03
MX2021014818A (es) 2022-01-18
JP6829210B2 (ja) 2021-02-10
WO2016156450A1 (fr) 2016-10-06

Similar Documents

Publication Publication Date Title
AR104156A1 (es) Anticuerpos monoclonales anti-cd303
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
CY1122940T1 (el) Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1
CY1117606T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
BR112019008675A2 (pt) roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor.
UA111934C2 (uk) ТРАНСГЕННА РОСЛИНА, ЩО МІСТИТЬ ДНК, ЯКА КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Vip3Ab, І ДНК, ЯКА КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Cry1Fa, СТІЙКА ДО ЛУСКОКРИЛИХ ШКІДНИКІВ
MX361533B (es) Anticuerpos anti-cd22.
WO2015021354A3 (en) Pesticidal toxin active against coleopteran and/or hemipteran insects
ECSP18022819A (es) Proteínas inhibidoras de insectos novedosas
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
PH12016502024A1 (en) Tonoplast proton/sugar antiporter proteins and the use thereof to increase the saccharose concentration in a saccharose storage organ of plants
MX2023010875A (es) Tiburón arcoíris transgénico.
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
BR112015002689A2 (pt) polinucleotídeo isolado, construção de dna recombinante, vetor, célula, vegetal transgênico, semente transgênica, método de expressão de uma sequência de codificação, métodos para alterar de maneira transgênica um aspecto comercializável do vegetal, para alterar a expressão de pelo menos um fragmento heterólogo de ácido nucleico e para expressar uma proteína fluorescente e vegetal estavelmente transformado.
CO2019010530A2 (es) Métodos para mejorar rasgos en plantas
AR110040A1 (es) Proteínas de unión biespecíficas
MX2021006100A (es) Barbo transgenico.
WO2014146181A3 (pt) Promotor específico de folhas, gene quimérico, vetor de recombinante, planta ou parte de planta transformada e métodos contendo promotor específico de folhas para modificar a expressão de genes de interesse em plantas
AR110191A1 (es) Integración específica en un sitio de un transgén mediante una recombinación intragenómica a través de una vía de reparación por unión de extremos no homólogos
PH12018501101A1 (en) Method for modifying lateral budding
UY37102A (es) Moléculas de ácido nucleico gawky (gw) para controlar plagas de insectos, vector, plantas y métodos relacionados